These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 33132254)
41. Beyond Ketamine: New Approaches to the Development of Safer Antidepressants. Chaki S Curr Neuropharmacol; 2017; 15(7):963-976. PubMed ID: 28228087 [TBL] [Abstract][Full Text] [Related]
42. The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice. Lindholm JS; Autio H; Vesa L; Antila H; Lindemann L; Hoener MC; Skolnick P; Rantamäki T; Castrén E Neuropharmacology; 2012 Jan; 62(1):391-7. PubMed ID: 21867718 [TBL] [Abstract][Full Text] [Related]
43. The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways. Ren L Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110910. PubMed ID: 38061484 [TBL] [Abstract][Full Text] [Related]
44. Role of a VGF/BDNF/TrkB Autoregulatory Feedback Loop in Rapid-Acting Antidepressant Efficacy. Jiang C; Lin WJ; Salton SR J Mol Neurosci; 2019 Jul; 68(3):504-509. PubMed ID: 30022437 [TBL] [Abstract][Full Text] [Related]
45. A hypothesis of monoamine (5-HT) - Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery. Li YF Pharmacol Ther; 2020 Apr; 208():107494. PubMed ID: 31991195 [TBL] [Abstract][Full Text] [Related]
46. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants. Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; Zuo Y; Shen H; Wei Y; Zhao L Pharmacol Res; 2023 Aug; 194():106837. PubMed ID: 37379962 [TBL] [Abstract][Full Text] [Related]
47. mTORC1-dependent signaling pathway underlies the rapid effect of creatine and ketamine in the novelty-suppressed feeding test. Pazini FL; Rosa JM; Camargo A; Fraga DB; Moretti M; Siteneski A; Rodrigues ALS Chem Biol Interact; 2020 Dec; 332():109281. PubMed ID: 33022268 [TBL] [Abstract][Full Text] [Related]
48. R (-)-methoxetamine exerts rapid and sustained antidepressant effects and fewer behavioral side effects relative to S (+)-methoxetamine. Botanas CJ; Perez Custodio RJ; Kim HJ; de la Pena JB; Sayson LV; Ortiz DM; Kim M; Lee HJ; Acharya S; Kim KM; Lee CJ; Ryu JH; Lee YS; Cheong JH Neuropharmacology; 2021 Aug; 193():108619. PubMed ID: 34023336 [TBL] [Abstract][Full Text] [Related]
49. The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus. Barrutieta-Arberas I; Ortuzar N; Vaquero-Rodríguez A; Picó-Gallardo M; Bengoetxea H; Guevara MA; Gargiulo PA; Lafuente JV Exp Biol Med (Maywood); 2023 Apr; 248(7):588-595. PubMed ID: 37158084 [TBL] [Abstract][Full Text] [Related]
50. Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures. Lepack AE; Bang E; Lee B; Dwyer JM; Duman RS Neuropharmacology; 2016 Dec; 111():242-252. PubMed ID: 27634096 [TBL] [Abstract][Full Text] [Related]
51. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Yang B; Zhang JC; Han M; Yao W; Yang C; Ren Q; Ma M; Chen QX; Hashimoto K Psychopharmacology (Berl); 2016 Oct; 233(19-20):3647-57. PubMed ID: 27488193 [TBL] [Abstract][Full Text] [Related]
52. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Hashimoto K Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725 [TBL] [Abstract][Full Text] [Related]
53. Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect. Bottemanne H; Berkovitch L; Gauld C; Balcerac A; Schmidt L; Mouchabac S; Fossati P Neurosci Biobehav Rev; 2023 Nov; 154():105410. PubMed ID: 37793581 [TBL] [Abstract][Full Text] [Related]
54. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. Duman RS F1000Res; 2018; 7():. PubMed ID: 29899972 [TBL] [Abstract][Full Text] [Related]
55. Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine. Dong C; Zhang JC; Yao W; Ren Q; Ma M; Yang C; Chaki S; Hashimoto K Int J Neuropsychopharmacol; 2017 Mar; 20(3):228-236. PubMed ID: 27765808 [TBL] [Abstract][Full Text] [Related]
56. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Monteggia LM; Gideons E; Kavalali ET Biol Psychiatry; 2013 Jun; 73(12):1199-203. PubMed ID: 23062356 [TBL] [Abstract][Full Text] [Related]
58. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038 [TBL] [Abstract][Full Text] [Related]
59. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Chiu CT; Scheuing L; Liu G; Liao HM; Linares GR; Lin D; Chuang DM Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25548109 [TBL] [Abstract][Full Text] [Related]
60. Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics. Kojic M; Saelens J; Kadriu B; Zarate CA; Kraus C Curr Top Behav Neurosci; 2022; 56():141-167. PubMed ID: 35312993 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]